3
Announcements
Trials
Browse
Landscape
Status
Available
1
Sponsor Class
INDUSTRY
1
Study Type
Expanded_access
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma, Large B-Cell, Diffuse
5
Recurrence
4
Burkitt Lymphoma
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Lymphoma, Follicular
3
Leukemia
2
Neoplasm, Residual
1
Lymphoma, B-Cell
1
Lymphoma
1
Interventions
Cyclophosphamide
61
Rituximab
50
fludarabine
34
Prednisone
33
Doxorubicin
28
Biopsy
26
Vincristine
25
Specimen Handling
22
Magnetic Resonance Spectroscopy
20
Bendamustine Hydrochloride
19
pembrolizumab
16
Lenalidomide
16
obinutuzumab
14
fludarabine phosphate
14
Etoposide
14
venetoclax
13
Tacrolimus
11
Mycophenolic Acid
10
Melphalan
10
Dexamethasone
10
zanubrutinib
9
ibrutinib
9
acalabrutinib
9
Radiotherapy
9
Gemcitabine
9
Cytarabine
9
Busulfan
9
Whole-Body Irradiation
8
Mesna
8
Filgrastim
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma
×
tisagenlecleucel
×
1 year
×
Clear all
NCT03601442
2026-04-23
Managed Access Programs for CTL019, Tisagenlecleucel
Novartis
Available